OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
SCHAUMBURG, Ill., March 23, 2016 -- Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) a leading provider of affordable pharmaceuticals to the hospital market, announced the hiring of Sean Brynjelsen as Executive Vice President, Business Development. In this newly created role, Mr. Brynjelsen will develop and execute a strategy to drive long-term growth through the acceleration of product licensing, acquisition of products and portfolios as well as the execution of other M&A activity. Mr. Brynjelsen will report directly to Allan Oberman, Sagent’s Chief Executive Officer.
Mr. Brynjelsen joins Sagent to lead the third objective of our “Triple E” growth strategy to execute on strategic M&A transactions to advance our growth and profitability, said Allan Oberman, chief executive officer of Sagent. “Sean has extensive experience in pharmaceutical transactions, strategic planning and product licensing/development, which makes him a great addition to our executive leadership team. This newly created position, in conjunction with the addition of our EVP of Global Operations earlier this quarter, fulfills our commitment to strengthen the leadership of Sagent and support the acceleration of our ability to execute on our growth strategy.”
Mr. Brynjelsen has over 20 years of transactional experience in the pharmaceutical industry with companies including Akorn, Hospira and Baxter. Most recently, he served as Senior Vice President, Global Business Development for Akorn where he completed over one hundred transactions including the acquisition of over 25 products contributing greater than $300 million of annual revenue. He earned an MBA degree from the University of Notre Dame and holds a Master of Science in Chemistry and a Bachelor of Science in BioChemistry from the University of Illinois.
About Sagent Pharmaceuticals
Sagent Pharmaceuticals, Inc., founded in 2006, is a leading provider of affordable pharmaceuticals to the hospital market. Sagent has created a unique, global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.
SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605
